Immunogenicity and safety of Sanofi Pasteur's Avaxim 80U pediatric vaccine followed by booster dose

Trial Profile

Immunogenicity and safety of Sanofi Pasteur's Avaxim 80U pediatric vaccine followed by booster dose

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Hepatitis A vaccine inactivated (Primary)
  • Indications Hepatitis A
  • Focus Pharmacodynamics
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 22 Sep 2008 Primary outcome identified as providing information concerning the immunogenicity of AVAXIM 80U Pediatric vaccine as reported by ClinicalTrials.gov.
    • 22 Sep 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 22 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top